Pliafx Flo
Lifenet Health
FDA Clearance Information
Pliafx flo received FDA clearance through the 510k pathway on November 21, 2024. It is manufactured by Lifenet Health and classified as a Class 2 device under product code MBP.
What It Is
FDA-Cleared Indications
- Used for embolization procedures when occlusion or reduction of blood flow is clinically indicated.
- FDA clearance was granted under product code MBP, which covers embolization devices.
- Specific clinical indications should be confirmed in the current FDA-cleared labeling and instructions for use.
Clinical Applications
- Catheter-based embolization procedures performed to occlude or reduce blood flow in a targeted vessel.
- Embolization as part of treatment planning for selected tumors or vascular lesions when included in the treating physician's clinical indication.
- Use in interventional procedures where controlled vessel occlusion is required.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- The available record does not provide device dimensions, delivery-system compatibility, or the complete instructions for use; these details should be checked in the current manufacturer labeling.
- The treating physician selects the embolization approach, access site, catheter system, and device size based on the target vessel and anatomy.
- Potential risks of embolization include non-target embolization, ischemia, bleeding, infection, vessel injury, and recurrence or persistence of the treated condition.
- MRI safety and conditional-use requirements are not established by the information provided here; confirm the device's current MRI labeling before scanning.
- Contraindications, warnings, storage requirements, and handling instructions should be reviewed in the FDA-cleared labeling.
Frequently Asked Questions
What are the clinical indications for pliafx flo?
Pliafx flo is indicated for use in embolization procedures to occlude blood vessels in conditions such as tumors and vascular malformations.
What outcomes have been reported in clinical studies?
Studies report successful embolization and improved clinical outcomes, with significant reductions in blood flow to targeted areas.
What complications have been reported?
Reported complications include minor adverse events like localized pain and inflammation, with a low incidence of serious complications.